NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX) today announced the commercial launch of BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple ...

The TG‑7FX is UL 864 Listed for use in a UL 864 Listed enclosure certified, reinforcing its suitability for commercial fire signaling applications. Compact in size and efficient in power consumption, ...

Half a year after the FDA snatched back an approval for TG Therapeutics’ first-in-class lymphoma med Ukoniq, the company has landed a regulatory win. Wednesday, TG snared U.S. approval for its ...

Telguard, a leader in security and life safety technologies, is pleased to bring to market the latest addition to its multi-carrier family of products. The new TG-7FEM multi-carrier 5G LTE-M and ...

TG Therapeutics recently completed a US$100 million share repurchase program, buying back approximately 3.5 million shares, and the Board of Directors has authorized an additional US$100 million ...

The Telguard TG-7E-V Dual Path Internet and 5G LTE-M Commercial Intrusion Communicator is a robust alarm communicator designed for commercial security applications. It offers dual communication ...

The FDA surprised TG Therapeutics (TGTX) with the early approval of Ukoniq (umbralisib) for the treatment of relapsed/refractory marginal zone lymphoma (‘MZL’) but also for relapsed/refractory ...

Telguard's streamlined LTE fire communicator is designed to simplify installation while maintaining reliable signal delivery.

Telguard TG-7E-V Dual Path Internet and 5G LTE-M Commercial Intrusion Communicator, Verizon Limited-Time Offer - While Supplies Last The Telguard TG-7E-V Dual Path Internet and 5G LTE-M Commercial ...